Sanofi’s new dengue challenge: find a diagnostic that will make its vaccine safe to use
"It would be a travesty not to fully leverage the benefits of this vaccine in the context of public health. So we are absolutely behind that, trying to make it…
Newly published data reveal in greater depth the problem Sanofi Pasteur’s Dengvaxia vaccine poses to children who have never experienced a dengue infection.
The findings, first revealed by the company last November, were the basis of an April decision by a World Health Association expert panel to recommend the vaccine only be given to children who have tested positive for a prior dengue infection. There is no such test at the moment.
Despite the publication in the , a Sanofi official said the company remains committed to finding a way to allow the vaccine to be
